# US 10,478,407 B2 · Pharmaceutical composition for viral infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,478,407 B2 - Document ID: US10478407B2 - Status: Granted - Kind: B2 - Application number: 16/283,683 - Filed: 2019-02-22 - Published: 2019-08-29 - Granted: 2019-11-19 - Earliest claimed: 2018-02-23 - Assignees: The Administrators of the Tulane Educational Fund - Applicants: The Administrators of the Tulane Educational Fund - Inventors: Chad Roy - Web page: https://patentgrep.com/patent/US10478407B2 ## CPC - A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205) - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 47/02: Inorganic compounds - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/12: Antivirals - A61P 31/14: for RNA viruses - A61P 31/18: for HIV - A61P 31/20: for DNA viruses - A61P 31/22: for herpes viruses - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Disclosed herein are topical compositions comprising a quaternary ammonium salt and optionally ammonium chloride and/or stabilized chlorine dioxide. Also disclosed herein are methods of reducing the severity and/or duration of a dermal and or mucosal infection such as herpes or shingles. Also disclosed herein are methods of preventing the spread of a viral infection such as HIV. Also disclosed herein are methods of treating a viral infection such as keratoconjunctivitis. ## Claims ### Claim 1 A method of reducing the severity or the duration of the symptoms of a viral infection selected from herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella zoster virus (VZV), in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 2 (depends on 1) The method of claim 1, wherein the viral infection is caused by the herpes simplex virus. ### Claim 3 (depends on 1) The method of claim 1, wherein the symptoms of the infection are selected from lesions, pain, fever, swollen lymph nodes, and any combinations thereof. ### Claim 4 (depends on 1) The method of claim 1, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is a mixture of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 5 (depends on 1) The method of claim 1, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C12-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 6 (depends on 1) The method of claim 1, wherein the pharmaceutical composition is essentially free of alkyl(ethylbenzyl)dimethyl ammonium salt having an alkyl of less than 12 carbons or more than 14 carbons. ### Claim 7 (depends on 1) The method of claim 1, wherein the pharmaceutical composition is essentially free of benzalkonium chloride. ### Claim 8 (depends on 1) The method of claim 1, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w. ### Claim 9 (depends on 1) The method of claim 1, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w. ### Claim 10 (depends on 1) The method of claim 1, wherein the pharmaceutical composition is in the form of an aerosol, a solution, a lotion, a gel, an ointment, a cream, a foam, a paste, or any combinations thereof. ### Claim 11 (depends on 1) The method of claim 1, wherein the subject in need thereof is immuno-compromised. ### Claim 12 A method of preventing the spread of a viral infection selected from influenza virus, the herpes simplex virus, the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus, the human papillomavirus (HPV), the ebolavirus, and an adenovirus, in a subject in need thereof, the method comprising administering to the subject in need thereof a pharmaceutical composition comprising C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 13 (depends on 12) The method of claim 12, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is a mixture of C12-alkyl(ethylbenzyl)dimethylammonium chloride and C14-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 14 (depends on 12) The method of claim 12, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is C12-alkyl(ethylbenzyl)dimethylammonium chloride. ### Claim 15 (depends on 12) The method of claim 12, wherein the pharmaceutical composition is essentially free of alkyl(ethylbenzyl)dimethyl ammonium salt having an alkyl of less than 12 carbons or more than 14 carbons. ### Claim 16 (depends on 12) The method of claim 12, wherein the pharmaceutical composition is essentially free of benzalkonium chloride. ### Claim 17 (depends on 12) The method of claim 12, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.0001% to about 10% w/w. ### Claim 18 (depends on 12) The method of claim 12, wherein the C12-C14-alkyl(ethylbenzyl)dimethylammonium chloride is present in an amount ranging from about 0.001% to about 1% w/w. ### Claim 19 (depends on 12) The method of claim 12, wherein the subject in need thereof is immuno-compromised.